GLPwatch
Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status
NCT02118376 · Unknown status
Last updated 2026-05-28This clinical trial is testing whether a GLP-1 receptor agonist can change body fat distribution and reduce inflammation in adults with obesity.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 20 people Planned (estimated).
Who can join Ages 18–65 · female only
Timeline Started 2014-08 · est. completion 2014-12
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT02118376 ↗
Description as written by the study sponsor.
GLP-1 receptor agonists promote fat redistribution in obese women with type 2 diabetes, reduce liver fat content, improve the inflammation state
Treatments tested
- Exenatide also known as Byetta Drug
5ug bid,Subcutaneous injection
| Main thing measured | Dual energy X-ray absorptiometry |
|---|---|
| Sponsor | Shanghai 10th People's Hospital |
| Conditions studied | Obesity |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02118376 ↗